Predisposing factors to heart failure in diabetic nephropathy: a look at the sympathetic nervous system hyperactivity.
Predisposing factors to heart failure in diabetic nephropathy: a look at the sympathetic nervous system hyperactivity. Aging Clin Exp Res. 2018 Jun 01;: Authors: Komici K, Femminella GD, de Lucia C, Cannavo A, Bencivenga L, Corbi G, Leosco D, Ferrara N, Rengo G Abstract Diabetes mellitus (DM) and heart failure (HF) are frequent comorbidities among elderly patients. HF, a leading cause of mortality and morbidity worldwide, is characterized by sympathetic nervous system hyperactivity. The prevalence of diabetes mellitus (DM) is rapidly growing and the risk of developing HF is higher among DM patients. DM is responsible for several macro- and micro-angiopathies that contribute to the development of coronary artery disease (CAD), peripheral artery disease, retinopathy, neuropathy and diabetic nephropathy (DN) as well. Independently of CAD, chronic kidney disease (CKD) and DM increase the risk of HF. Individuals with diabetic nephropathy are likely to present a distinct pathological condition, defined as diabetic cardiomyopathy, even in the absence of hypertension or CAD, whose pathogenesis is only partially known. However, several hypotheses have been proposed to explain the mechanism of diabetic cardiomyopathy: increased oxidative stress, altered substrate metabolism, mitochondrial dysfunction, activation of renin-angiotensin-aldosterone system (RAAS), insulin resistance, and autonomic dysfunction. In this review, we will focus on the involvement of sympath...
Publication date: Available online 21 January 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): Chantal Mathieu
Publication date: Available online 21 January 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): Inge B Halberg, Karsten Lyby, Karsten Wassermann, Tim Heise, Eric Zijlstra, Leona Plum-MörschelSummaryBackgroundOral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate. We investigated the efficacy and safety of I338 versus subcutaneous insulin glargine (IGlar) in patients with type 2 diabetes.MethodsThis was a phase 2, 8-week, randomised, double-blind, double-dummy, active-controlled, parallel trial completed at two research institutes i...
ConclusionsIn conclusion, metabolically health status and BMI are associated with risk of depression. Metabolically unhealthy situation increased risk of depression greater than metabolically healthy status.
ConclusionInverse correlation present between plasma zinc, calcium and magnesium level and BMI and waist circumference, but positive correlation seen between phosphate level and waist circumference. Further studies are needed to evaluate the effect of dietary or supplemental interventions on obesity and central obesity.
ConclusionObesity defined by a high BMI was not found to be a significant risk factor for micro/macroalbuminuria in hypertensive patients with a poor estimated glomerular filtration rate, when diabetes mellitus and the low eGFR value act as confounders.
ConclusionsIn this study, age was the strongest determinant of diabetes. And then type 2 diabetes is mainly attributable to WHR, significantly more so in women than men. Therefore, central obesity probably should be considered as a major strategy for reducing incidence of type 2 diabetes.
Conclusion: These exploratory findings indicate that patients with NeP across different etiologies are medically complex and experience impaired function across multiple domains. PMID: 30662281 [PubMed]
Conclusion: Evaluation of chronic pain patients in Brazil yielded a 14.5% probable NeP prevalence. NSAIDs and opioids were commonly used, and there was a high incidence of NeP-related symptoms with varying levels of dysfunction across subtypes. PMID: 30662280 [PubMed]
ConclusionsThere is significant left ventricular systolic impairment detected by global longitudinal strain (GLS) in spite of preserved left ventricular ejection fraction.
This study was designed to screen the potential molecules and pathways implicated with DCM. GSE26887 involving 5 control individuals and 7 DCM patients was selected from the GEO database to identify the differentially expressed genes (DEGs). DAVID was applied to perform gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. A protein-protein interaction (PPI) network was also constructed to visualize the interactions among these DEGs. To further validate significant genes and pathways, quantitative real-time PCR (qPCR) and Western blot were performed. A total of 236 DEGs were captured, includin...
More News: Brain | Cardiology | Cardiomyopathy | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Endocrinology | Heart | Heart Failure | Hyperactivity | Hypertension | Insulin | Mitochondrial Disease | Neurology | Peripheral Vascular Disease (PVD) | Reflex Sympathetic Dystrophy | Urology & Nephrology